New shot for advanced cancer enters human testing

NCT ID NCT07123129

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times

Summary

This early-stage study tests an experimental drug called SHR-7782 in 200 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow their growth. Participants must have measurable tumors and be in relatively good health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED MALIGNANCY